Core Viewpoint - Innovent Biologics' partner Ollin has reported positive topline results from the Phase 1b JADE clinical study, indicating that OLN324, a next-generation VEGF/Ang2 bispecific antibody, shows superior efficacy compared to faricimab in treating diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) [1][5]. Group 1: Clinical Study Results - OLN324 demonstrated faster and greater retinal drying compared to faricimab, with 4mg treated patients showing mean improvements in retinal drying that were approximately 75% greater at Week 1 and about 50% greater at Week 12 [2][3]. - Nearly 90% of patients treated with OLN324 4mg achieved absence of DME at Week 12, compared to 57% of faricimab patients [2]. - All treatment groups showed equivalent anatomic outcomes in wAMD, with sustained improvements in vision noted across both DME and wAMD treatment groups [3]. Group 2: Clinical Significance - The observed differences in speed and extent of retinal drying with OLN324 versus faricimab are considered clinically significant, potentially leading to broad utility for OLN324 across major retinal diseases [4]. - OLN324 is the first therapy to demonstrate superior anatomic efficacy compared to faricimab in a head-to-head clinical trial, validating its higher potency and dosing [5]. Group 3: Market Potential - OLN324 has the potential to become the new standard of care in the approximately $15 billion global market for retinal therapeutics [5]. - The successful results from the JADE Phase 1b trial position OLN324 favorably for future global Phase 3 studies in both DME and wAMD [5][6]. Group 4: Safety Profile - A favorable safety profile was observed with OLN324, with no cases of intraocular inflammation reported during the study, contrasting with one case in the faricimab group [9].